- Home
- CREV vs PRTG Comparison
CREV vs PRTG Comparison
Compare CREV & PRTG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CREV
- PRTG
- Stock Information
- Founded
- CREV 2007
- PRTG 1973
- Country
- CREV Ireland
- PRTG British Virgin Islands
- Employees
- CREV N/A
- PRTG N/A
- Industry
- CREV
- PRTG Oil & Gas Production
- Sector
- CREV
- PRTG Energy
- Exchange
- CREV Nasdaq
- PRTG Nasdaq
- Market Cap
- CREV 4.8M
- PRTG 4.7M
- IPO Year
- CREV N/A
- PRTG N/A
- Fundamental
- Price
- CREV $5.05
- PRTG $4.10
- Analyst Decision
- CREV Strong Buy
- PRTG
- Analyst Count
- CREV 1
- PRTG 0
- Target Price
- CREV $39.00
- PRTG N/A
- AVG Volume (30 Days)
- CREV 1.6M
- PRTG 128.0K
- Earning Date
- CREV 01-01-0001
- PRTG 02-26-2025
- Dividend Yield
- CREV N/A
- PRTG N/A
- EPS Growth
- CREV N/A
- PRTG N/A
- EPS
- CREV N/A
- PRTG N/A
- Revenue
- CREV $39,261,077.00
- PRTG N/A
- Revenue This Year
- CREV $40.76
- PRTG N/A
- Revenue Next Year
- CREV $86.18
- PRTG N/A
- P/E Ratio
- CREV N/A
- PRTG N/A
- Revenue Growth
- CREV 41.52
- PRTG N/A
- 52 Week Low
- CREV $2.00
- PRTG $2.10
- 52 Week High
- CREV $23.98
- PRTG $25.16
- Technical
- Relative Strength Index (RSI)
- CREV 49.46
- PRTG 42.95
- Support Level
- CREV $4.72
- PRTG $3.86
- Resistance Level
- CREV $5.90
- PRTG $4.98
- Average True Range (ATR)
- CREV 0.93
- PRTG 0.54
- MACD
- CREV -0.24
- PRTG -0.15
- Stochastic Oscillator
- CREV 6.98
- PRTG 11.53
About CREV Carbon Revolution Public Limited
Carbon Revolution PLC is an Australian-based technology company manufacturing carbon fiber wheels. It is an OEM supplier and a world-wide manufacturer of lightweight technology carbon fibre wheels to the automotive industry. The Company supplies wheels to OEMs across the globe for luxury and high-performance vehicles and SUVs, and is developing wheels for electric vehicles under contract for its OEM customers. The company generates maximum revenue Internationally.
About PRTG Portage Biotech Inc.
Portage Biotech Inc is engaged in researching and developing pharmaceutical and biotech products through clinical proof of concept with an initial focus on unmet clinical needs. It is an immune-oncology company focused on overcoming immune resistance and currently managing 10 immuno-oncology assets at various development stages. Its pipeline products include IMM-60; IMM60 + Cell Therapy; (IMM60 / NY-ESO-1) + Keytruda and others.